Published in Cell Cycle on October 28, 2005
Acute effects of leptin require PI3K signaling in hypothalamic proopiomelanocortin neurons in mice. J Clin Invest (2008) 2.77
Recognizing and exploiting differences between RNAi and small-molecule inhibitors. Nat Chem Biol (2007) 2.31
PI3K in cancer: divergent roles of isoforms, modes of activation and therapeutic targeting. Nat Rev Cancer (2015) 2.10
Class IA phosphoinositide 3-kinases are obligate p85-p110 heterodimers. Proc Natl Acad Sci U S A (2007) 1.98
A regulatory subunit of phosphoinositide 3-kinase increases the nuclear accumulation of X-box-binding protein-1 to modulate the unfolded protein response. Nat Med (2010) 1.93
p85α SH2 domain phosphorylation by IKK promotes feedback inhibition of PI3K and Akt in response to cellular starvation. Mol Cell (2012) 1.76
Suppression of PTEN function increases breast cancer chemotherapeutic drug resistance while conferring sensitivity to mTOR inhibitors. Oncogene (2008) 1.73
Soluble epoxide hydrolase deficiency alters pancreatic islet size and improves glucose homeostasis in a model of insulin resistance. Proc Natl Acad Sci U S A (2011) 1.45
The phosphoinositide 3-kinase regulatory subunit p85alpha can exert tumor suppressor properties through negative regulation of growth factor signaling. Cancer Res (2010) 1.41
PI3K signaling in glioma--animal models and therapeutic challenges. Brain Pathol (2009) 1.36
p85 Associates with unphosphorylated PTEN and the PTEN-associated complex. Mol Cell Biol (2009) 1.36
Targeting the phosphatidylinositol 3-kinase signaling pathway in breast cancer. Oncologist (2011) 1.32
ADP-ribosylation factor 1 controls the activation of the phosphatidylinositol 3-kinase pathway to regulate epidermal growth factor-dependent growth and migration of breast cancer cells. J Biol Chem (2008) 1.27
Involvement of Akt and mTOR in chemotherapeutic- and hormonal-based drug resistance and response to radiation in breast cancer cells. Cell Cycle (2011) 1.17
Involvement of Akt-1 and mTOR in sensitivity of breast cancer to targeted therapy. Oncotarget (2011) 1.16
The Ras-PI3K signaling pathway is involved in clathrin-independent endocytosis and the internalization of influenza viruses. PLoS One (2011) 1.05
Roles of genetic variants in the PI3K and RAS/RAF pathways in susceptibility to endometrial cancer and clinical outcomes. J Cancer Res Clin Oncol (2011) 1.04
p85alpha regulates osteoblast differentiation by cross-talking with the MAPK pathway. J Biol Chem (2011) 0.91
Abi1, a critical molecule coordinating actin cytoskeleton reorganization with PI-3 kinase and growth signaling. FEBS Lett (2012) 0.89
Altered glucose homeostasis in mice with liver-specific deletion of Src homology phosphatase 2. J Biol Chem (2010) 0.87
ERK-mediated NGF signaling in the rat septo-hippocampal pathway diminishes with age. Psychopharmacology (Berl) (2006) 0.86
Androgen deprivation induces phenotypic plasticity and promotes resistance to molecular targeted therapy in a PTEN-deficient mouse model of prostate cancer. Carcinogenesis (2014) 0.86
PIK3R1 negatively regulates the epithelial-mesenchymal transition and stem-like phenotype of renal cancer cells through the AKT/GSK3β/CTNNB1 signaling pathway. Sci Rep (2015) 0.85
The p85 regulatory subunit of PI3K mediates cAMP-PKA and insulin biological effects on MCF-7 cell growth and motility. ScientificWorldJournal (2014) 0.83
Protein-tyrosine phosphatase 1B substrates and metabolic regulation. Semin Cell Dev Biol (2014) 0.82
Disruption of Abi1/Hssh3bp1 expression induces prostatic intraepithelial neoplasia in the conditional Abi1/Hssh3bp1 KO mice. Oncogenesis (2012) 0.82
p85α is a microRNA target and affects chemosensitivity in pancreatic cancer. J Surg Res (2015) 0.81
Apolipoprotein E reduces food intake via PI3K/Akt signaling pathway in the hypothalamus. Physiol Behav (2011) 0.81
PIK3R1 targeting by miR-21 suppresses tumor cell migration and invasion by reducing PI3K/AKT signaling and reversing EMT, and predicts clinical outcome of breast cancer. Int J Oncol (2015) 0.81
Insulin resistance uncoupled from dyslipidemia due to C-terminal PIK3R1 mutations. JCI Insight (2016) 0.76
Neomorphic mutations create therapeutic challenges in cancer. Oncogene (2016) 0.75
Dysregulations in the PI3K pathway and targeted therapies for head and neck squamous cell carcinoma. Oncotarget (2017) 0.75
MicroRNA-Related Polymorphisms in PI3K/Akt/mTOR Pathway Genes Are Predictive of Limited-Disease Small Cell Lung Cancer Treatment Outcomes. Biomed Res Int (2017) 0.75
Emerging Role of MicroRNAs in mTOR Signaling. Cell Mol Life Sci (2017) 0.75
Eugenol alleviated breast precancerous lesions through HER2/PI3K-AKT pathway-induced cell apoptosis and S-phase arrest. Oncotarget (2017) 0.75
Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science (2009) 49.82
MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science (2007) 32.68
AKT/PKB signaling: navigating downstream. Cell (2007) 31.26
Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature (2009) 19.65
The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth. Nature (2008) 18.20
The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nat Rev Genet (2006) 17.19
Scansite 2.0: Proteome-wide prediction of cell signaling interactions using short sequence motifs. Nucleic Acids Res (2003) 15.74
Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers. Nat Med (2008) 14.47
The kinase LKB1 mediates glucose homeostasis in liver and therapeutic effects of metformin. Science (2005) 12.35
The tumor suppressor LKB1 kinase directly activates AMP-activated kinase and regulates apoptosis in response to energy stress. Proc Natl Acad Sci U S A (2004) 12.30
Ras, PI(3)K and mTOR signalling controls tumour cell growth. Nature (2006) 12.13
Identification of the tuberous sclerosis complex-2 tumor suppressor gene product tuberin as a target of the phosphoinositide 3-kinase/akt pathway. Mol Cell (2002) 11.65
Large-scale characterization of HeLa cell nuclear phosphoproteins. Proc Natl Acad Sci U S A (2004) 10.78
Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer. J Clin Invest (2008) 10.74
Pyruvate kinase M2 is a phosphotyrosine-binding protein. Nature (2008) 9.77
Tuberous sclerosis complex gene products, Tuberin and Hamartin, control mTOR signaling by acting as a GTPase-activating protein complex toward Rheb. Curr Biol (2003) 8.25
Bidirectional transport of amino acids regulates mTOR and autophagy. Cell (2009) 7.88
The LKB1 tumor suppressor negatively regulates mTOR signaling. Cancer Cell (2004) 7.77
Targeting the PI3K-Akt pathway in human cancer: rationale and promise. Cancer Cell (2003) 7.42
Oncogenic Kras maintains pancreatic tumors through regulation of anabolic glucose metabolism. Cell (2012) 7.36
The molecular basis for phosphodependent substrate targeting and regulation of Plks by the Polo-box domain. Cell (2003) 7.04
Proteomic screen finds pSer/pThr-binding domain localizing Plk1 to mitotic substrates. Science (2003) 6.97
Phosphoglycerate dehydrogenase diverts glycolytic flux and contributes to oncogenesis. Nat Genet (2011) 6.89
Glutamine supports pancreatic cancer growth through a KRAS-regulated metabolic pathway. Nature (2013) 6.53
ErbB-3 mediates phosphoinositide 3-kinase activity in gefitinib-sensitive non-small cell lung cancer cell lines. Proc Natl Acad Sci U S A (2005) 6.35
A colorectal cancer classification system that associates cellular phenotype and responses to therapy. Nat Med (2013) 6.09
Phosphoproteomic analysis identifies Grb10 as an mTORC1 substrate that negatively regulates insulin signaling. Science (2011) 5.73
Allelic dilution obscures detection of a biologically significant resistance mutation in EGFR-amplified lung cancer. J Clin Invest (2006) 5.73
Inhibition of pyruvate kinase M2 by reactive oxygen species contributes to cellular antioxidant responses. Science (2011) 5.72
A PtdInsP(3)- and Rho GTPase-mediated positive feedback loop regulates neutrophil polarity. Nat Cell Biol (2002) 5.58
Tyrosine phosphorylation inhibits PKM2 to promote the Warburg effect and tumor growth. Sci Signal (2009) 5.57
Evidence for an alternative glycolytic pathway in rapidly proliferating cells. Science (2010) 5.44
Breast cancer-associated PIK3CA mutations are oncogenic in mammary epithelial cells. Cancer Res (2005) 5.07
A rapid method for determining protein kinase phosphorylation specificity. Nat Methods (2004) 5.04
Tuberous sclerosis complex-1 and -2 gene products function together to inhibit mammalian target of rapamycin (mTOR)-mediated downstream signaling. Proc Natl Acad Sci U S A (2002) 4.93
High frequency of PIK3R1 and PIK3R2 mutations in endometrial cancer elucidates a novel mechanism for regulation of PTEN protein stability. Cancer Discov (2011) 4.78
Protein sequences from mastodon and Tyrannosaurus rex revealed by mass spectrometry. Science (2007) 4.41
Evidence that inositol polyphosphate 4-phosphatase type II is a tumor suppressor that inhibits PI3K signaling. Cancer Cell (2009) 4.30
Differential effects of gefitinib and cetuximab on non-small-cell lung cancers bearing epidermal growth factor receptor mutations. J Natl Cancer Inst (2005) 4.19
Glucose addiction of TSC null cells is caused by failed mTORC1-dependent balancing of metabolic demand with supply. Mol Cell (2010) 4.07
Rheb fills a GAP between TSC and TOR. Trends Biochem Sci (2003) 3.90
Oncogenic B-RAF negatively regulates the tumor suppressor LKB1 to promote melanoma cell proliferation. Mol Cell (2009) 3.85
Akt/protein kinase B promotes organ growth in transgenic mice. Mol Cell Biol (2002) 3.68
The Crohn's disease protein, NOD2, requires RIP2 in order to induce ubiquitinylation of a novel site on NEMO. Curr Biol (2004) 3.54
Pyruvate kinase M2 activators promote tetramer formation and suppress tumorigenesis. Nat Chem Biol (2012) 3.40
The PHD finger of the chromatin-associated protein ING2 functions as a nuclear phosphoinositide receptor. Cell (2003) 3.36
Targeting the PI3K signaling pathway in cancer. Curr Opin Genet Dev (2009) 3.35
Feedback inhibition of Akt signaling limits the growth of tumors lacking Tsc2. Genes Dev (2005) 3.25
A murine lung cancer co-clinical trial identifies genetic modifiers of therapeutic response. Nature (2012) 3.24
PIK3CA mutation is associated with poor prognosis among patients with curatively resected colon cancer. J Clin Oncol (2009) 3.24
Pancreatic stellate cells support tumour metabolism through autophagic alanine secretion. Nature (2016) 3.13
Phosphoinositide 3-kinase catalytic subunit deletion and regulatory subunit deletion have opposite effects on insulin sensitivity in mice. Mol Cell Biol (2005) 3.09
The alternative splicing repressors hnRNP A1/A2 and PTB influence pyruvate kinase isoform expression and cell metabolism. Proc Natl Acad Sci U S A (2010) 3.08
Lin28 enhances tissue repair by reprogramming cellular metabolism. Cell (2013) 3.08
Retracted Positive and negative roles of p85 alpha and p85 beta regulatory subunits of phosphoinositide 3-kinase in insulin signaling. J Biol Chem (2003) 3.06
The C2 domain of PKCdelta is a phosphotyrosine binding domain. Cell (2005) 3.05
Hem-1 complexes are essential for Rac activation, actin polymerization, and myosin regulation during neutrophil chemotaxis. PLoS Biol (2006) 3.01
Chemical genetic screen for AMPKα2 substrates uncovers a network of proteins involved in mitosis. Mol Cell (2011) 2.99
Influence of threonine metabolism on S-adenosylmethionine and histone methylation. Science (2012) 2.98
Metabolic regulation of protein N-alpha-acetylation by Bcl-xL promotes cell survival. Cell (2011) 2.98
PARK2 deletions occur frequently in sporadic colorectal cancer and accelerate adenoma development in Apc mutant mice. Proc Natl Acad Sci U S A (2010) 2.91
ERK1/2-dependent phosphorylation and nuclear translocation of PKM2 promotes the Warburg effect. Nat Cell Biol (2012) 2.87
Divergent regulation of hepatic glucose and lipid metabolism by phosphoinositide 3-kinase via Akt and PKClambda/zeta. Cell Metab (2006) 2.82
Acute effects of leptin require PI3K signaling in hypothalamic proopiomelanocortin neurons in mice. J Clin Invest (2008) 2.77
The mTORC1 pathway stimulates glutamine metabolism and cell proliferation by repressing SIRT4. Cell (2013) 2.70
Reduced expression of the murine p85alpha subunit of phosphoinositide 3-kinase improves insulin signaling and ameliorates diabetes. J Clin Invest (2002) 2.65
Akt-RSK-S6 kinase signaling networks activated by oncogenic receptor tyrosine kinases. Sci Signal (2010) 2.64
Diverse biochemical properties of Shp2 mutants. Implications for disease phenotypes. J Biol Chem (2005) 2.60
Cancer metabolism: fatty acid oxidation in the limelight. Nat Rev Cancer (2013) 2.59
Combining a PI3K inhibitor with a PARP inhibitor provides an effective therapy for BRCA1-related breast cancer. Cancer Discov (2012) 2.53
The Mycobacterium tuberculosis serine/threonine kinases PknA and PknB: substrate identification and regulation of cell shape. Genes Dev (2005) 2.52
Increased insulin sensitivity in mice lacking p85beta subunit of phosphoinositide 3-kinase. Proc Natl Acad Sci U S A (2001) 2.49
Biomolecular characterization and protein sequences of the Campanian hadrosaur B. canadensis. Science (2009) 2.48
Molecular balance between the regulatory and catalytic subunits of phosphoinositide 3-kinase regulates cell signaling and survival. Mol Cell Biol (2002) 2.42
Systemic elevation of PTEN induces a tumor-suppressive metabolic state. Cell (2012) 2.39
PKM2 isoform-specific deletion reveals a differential requirement for pyruvate kinase in tumor cells. Cell (2013) 2.38
Substrate specificity and inhibitors of LRRK2, a protein kinase mutated in Parkinson's disease. Biochem J (2009) 2.33
Rac1 regulates the activity of mTORC1 and mTORC2 and controls cellular size. Mol Cell (2011) 2.32
IkappaB kinase beta phosphorylates the K63 deubiquitinase A20 to cause feedback inhibition of the NF-kappaB pathway. Mol Cell Biol (2007) 2.31
A co-clinical approach identifies mechanisms and potential therapies for androgen deprivation resistance in prostate cancer. Nat Genet (2013) 2.29
Metabolic flux and the regulation of mammalian cell growth. Cell Metab (2011) 2.27
Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature (2010) 2.21
Receptor tyrosine kinases exert dominant control over PI3K signaling in human KRAS mutant colorectal cancers. J Clin Invest (2011) 2.20
Regulation of epithelial tight junction assembly and disassembly by AMP-activated protein kinase. Proc Natl Acad Sci U S A (2007) 2.20
Overview of the Alliance for Cellular Signaling. Nature (2002) 2.15
Use of RNA interference-mediated gene silencing and adenoviral overexpression to elucidate the roles of AKT/protein kinase B isoforms in insulin actions. J Biol Chem (2003) 2.12
A label-free quantification method by MS/MS TIC compared to SILAC and spectral counting in a proteomics screen. Proteomics (2008) 2.11
Coordinated regulation of Toll-like receptor and NOD2 signaling by K63-linked polyubiquitin chains. Mol Cell Biol (2007) 2.06
The p85 regulatory subunit of phosphoinositide 3-kinase down-regulates IRS-1 signaling via the formation of a sequestration complex. J Cell Biol (2005) 2.04
mTOR drives its own activation via SCF(βTrCP)-dependent degradation of the mTOR inhibitor DEPTOR. Mol Cell (2011) 2.03
Characterization of KRAS rearrangements in metastatic prostate cancer. Cancer Discov (2011) 2.02
Stem cell metabolism in tissue development and aging. Development (2013) 2.01
Phosphorylation of the tumor suppressor CYLD by the breast cancer oncogene IKKepsilon promotes cell transformation. Mol Cell (2009) 2.00
Small molecule activation of PKM2 in cancer cells induces serine auxotrophy. Chem Biol (2012) 1.96
Role of phosphoinositide 3-kinase regulatory isoforms in development and actin rearrangement. Mol Cell Biol (2005) 1.94
Hitting the target: emerging technologies in the search for kinase substrates. Sci STKE (2002) 1.91
The structural basis for substrate and inhibitor selectivity of the anthrax lethal factor. Nat Struct Mol Biol (2003) 1.91
Heterogeneity of tumor-induced gene expression changes in the human metabolic network. Nat Biotechnol (2013) 1.91
Identification of small molecule inhibitors of pyruvate kinase M2. Biochem Pharmacol (2009) 1.86
Identification of small molecule inhibitors of anthrax lethal factor. Nat Struct Mol Biol (2003) 1.86